A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs ACI 24 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Sponsors AC Immune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Mar 2017 Interim analysis of the first three doses (cohort 1-3) published in an AC Immune media release.
    • 27 Apr 2012 Planned end date 9 Dec 2012 added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top